<?xml version="1.0" encoding="utf-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
>

<channel rdf:about="http://www.biochemj.org">
<title>BJ Metabolism Immediate Publications</title>
<link>http://www.biochemj.org</link>
<description>Biochemical Journal RSS feed -- BJ Metabolism Immediate Publications</description>
<prism:issn>0264-6021</prism:issn>
<prism:eIssn>1470-8728</prism:eIssn>
<prism:publicationName>Biochemical Journal</prism:publicationName>
<items>
 <rdf:Seq>
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120618" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111920" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120439" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120232" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120528" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120173" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112142" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112225" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112200" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120294" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120197" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111890" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120163" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112079" /> </rdf:Seq>
</items>
<image rdf:resource="http://www.biochemj.org/images/BJ_Name.gif" />
</channel>

<image rdf:about="http://www.biochemj.org/images/BJ_Name.gif">
<title>Biochemical Journal</title>
<url>http://www.biochemj.org/images/BJ_Name.gif</url>
<link>http://www.biochemj.org</link>
</image>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120618">
	<title><![CDATA[Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120618</link>
	<description><![CDATA[Selenium is an essential trace element in mammals, but is toxic at high levels. It is best known for its cancer prevention activity, but cancer cells are more sensitive to selenite toxicity than normal cells. Since selenite treatment leads to oxidative stress, and the thioredoxin system is a major antioxidative system, we examined the interplay between thioredoxin reductase 1 (TR1) and thioredoxin 1 (Trx1) deficiencies and selenite toxicity in DT cells, a malignant mouse cell line, and the corresponding parental NIH3T3 cells. TR1 deficient cells were far more sensitive to selenite toxicity than Trx1-deficient or control cells. In contrast, this effect was not seen in cells treated with hydrogen peroxide, suggesting that the increased sensitivity of TR1 deficiency to selenite was not due to oxidative stress caused by this compound. Further analyses revealed that only TR1-deficient cells manifested strongly enhanced production and secretion of glutathione, which was associated with increased sensitivity of the cells to selenite. The data uncover a new role of TR1 in cancer that is independent of Trx reduction and compensated for by the glutathione system. The data also suggest that the enhanced selenite toxicity of cancer cells and simultaneous inhibition of TR1 can provide a new avenue for cancer therapy.]]></description>
	<dc:creator>R Tobe, M Yoo, N Fradejas, B A Carlson, S Calvo, V N Gladyshev, D L Hatfield</dc:creator>
	<dc:date>2012-05-17T12:46:10Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20120618</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-05-17</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111920">
	<title><![CDATA[Effects of the novel mitochondrial protein mimitin in insulin-secreting cells]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111920</link>
	<description><![CDATA[Mimitin, a novel mitochondrial protein, has been shown to act as a molecular chaperone for the mitochondrial complex I and to regulate ATP synthesis. During type 1 diabetes development proinflammatory cytokines induce mitochondrial damage in pancreatic beta cells, inhibit ATP synthesis, and reduce glucose-induced insulin secretion. Mimitin was expressed in rat pancreatic islets including beta cells and decreased by cytokines. In the ob/ob mouse, a model of insulin resistance and obesity, mimitin expression was downregulated in liver and brain, upregulated in heart and kidney, but not affected in islets. To further analyze the impact of mimitin on beta cell function two beta cell lines, one with a low (INS1E) and another with a higher mimitin expression (MIN6) were studied. Mimitin overexpression protected INS1E cells against cytokine-induced caspase-3 activation, mitochondrial membrane potential reduction and ATP production inhibition, independently from the NFkB-iNOS pathway. Mimitin overexpression increased basal and glucose-induced insulin secretion and prevented cytokine-mediated suppression of insulin secretion. Mimitin knock-down in MIN6 cells had opposite effects to those observed after overexpression. Thus mimitin has the capacity to modulate pancreatic islet function and to reduce cytokine toxicity.]]></description>
	<dc:creator>K Hanzelka, L Skalniak, J Jura, S Lenzen, E Gurgul-Convey</dc:creator>
	<dc:date>2012-05-16T11:22:15Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111920</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-05-16</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120439">
	<title><![CDATA[MYSTERIOUS Ca 2{+}- INDEPENDENT MUSCULAR CONTRACTION : d{e}j{a} vu]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120439</link>
	<description><![CDATA[The permeabilized cells and muscle fibers technique allows to study the functional properties of mitochondria without their isolation, thus preserving intact all contacts with cellular structures, mostly cytoskeleton, to study the whole population of mitochondria in the cell in their natural surrounding and is increasingly used both in experimental and clinical studies. The functional parameters (affinity for ADP in regulation of respiration) of mitochondria in permeabilized myocytes or myocardial fibers are very different from those in isolated mitochondria in<i> vitro</i>. In this article we analyze the data showing the dependence of this parameter upon muscle contractile state. Most remarkable is the effect of recently described calcium- independent contraction of permeabilized muscle fibers induced by elevated temperatures (30-37&#x00B0;C). We show that very similar strong spontaneous calcium-independent contraction can be produced by proteolytic treatment of permeabilized muscle fibers that resulting in a disorganization of mitochondrial arrangement leading to significant increase of affinity for ADP. These data show that calcium-insensitive contraction may be related to the destruction of cytoskeleton structures by intracellular proteases. Therefore, use of their inhibitors is strongly advised at the step of permeabilization with careful washing of fibers or cells afterwards. Possible physiologically relevant relationship between calcium-regulated, ATP-dependent contraction and mitochondrial functional parameters is also discussed.]]></description>
	<dc:creator>A V. Kuznetsov, R Guzun, F Boucher, R Bagur, T Kaambre, V A Saks</dc:creator>
	<dc:date>2012-05-03T10:36:08Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20120439</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-05-03</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120232">
	<title><![CDATA[Deciphering the role of GLUT4 N-glycosylation in adipocyte and muscle cell models]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120232</link>
	<description><![CDATA[Glucose transporter GLUT4 is responsible for the insulin-induced uptake of glucose by muscle and fat cells. In non-stimulated (basal) cells, GLUT4 is retained intracellularly, while insulin stimulation leads to its translocation from storage compartments towards the cell surface. How GLUT4 is retained intracellularly is largely unknown. Previously, aberrant GLUT4 <i>N</i>-glycosylation has been linked to increased basal cell surface levels while <i>N</i>-glycosylation-deficient GLUT4 was found to be quickly degraded. As recycling and degradation of GLUT4 are positively correlated, we hypothesized that incorrect <i>N</i>-glycosylation of GLUT4 might reduce its intracellular retention resulting in an increased cell surface recycling, in increased basal cell surface levels, and in enhanced GLUT4 degradation. Here, we have studied <i>N</i>-glycosylation-deficient GLUT4 in detail in 3T3-L1 preadipocytes, 3T3-L1 adipocytes, and L6 myoblasts. We have found no alterations in retention, insulin response, internalization, or glucose transport activity. Degradation of the mutant molecule was increased, though once present at the cell surface, its degradation was identical to that of wild-type GLUT4. Our findings indicate that <i>N</i>-glycosylation is important for efficient trafficking of GLUT4 to its proper compartments, but once the transporter has arrived there, <i>N</i>-glycosylation plays no further major role in its intracellular traffic, nor in its functional activity.]]></description>
	<dc:creator>N Zaarour, M Berenguer, Y Le Marchand-Brustel, R Govers</dc:creator>
	<dc:date>2012-04-30T14:17:26Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20120232</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-04-30</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120528">
	<title><![CDATA[Characterization of an acetyltransferase that detoxifies aromatic chemicals in Legionella pneumophila]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120528</link>
	<description><![CDATA[<i>Legionella pneumophila</i> is an opportunistic pathogen and the causative agent of Legionnaires&#x2019; disease. Despite being exposed to many chemical compounds in its natural and man-made habitats (natural aquatic biotopes and man-made water systems), <i>L. pneumophila</i> is able to adapt and survive in these environments. The molecular mechanisms by which this bacterium detoxifies these chemicals remain poorly understood. In particular, the expression and functions of xenobiotic-metabolizing enzymes (XME) that could contribute to chemical detoxification in <i>L. pneumophila</i> have been poorly documented at the molecular and functional levels. We report here the identification and biochemical and functional characterization of a unique acetyltransferase that metabolizes aromatic amine chemicals in three characterized clinical strains of <i>L. pneumophila</i> (Paris, Lens, and Philadelphia). Strain-specific sequence variations in this enzyme, an atypical member of the arylamine <i>N</i>-acetyltransferase family (EC 2.3.1.5), produce enzymatic variants with different structural and catalytic properties. Functional inactivation and complementation experiments showed that this acetyltransferase allows <i>L. pneumophila</i> to detoxify aromatic amine chemicals and grow in their presence. Our study provides a new enzymatic mechanism by which the opportunistic pathogen <i>L. pneumophila</i> biotransforms and detoxifies toxic aromatic chemicals. These data also emphasize the role of xenobiotic-metabolizing enzymes in the environmental adaptation of certain prokaryotes.]]></description>
	<dc:creator>X Kubiak, D Dervins-Ravault, B Pluvinage, A Chaffotte, L Gomez-Valero, J Dairou, F Busi, J Dupret, C Buchrieser, F Rodrigues-Lima</dc:creator>
	<dc:date>2012-04-30T13:36:25Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20120528</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-04-30</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120173">
	<title><![CDATA[Distinct Functional Roles of the Two Terminal Halves of Eukaryotic Phosphofructokinase]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120173</link>
	<description><![CDATA[Eukaryotic phosphofructokinase, a key regulatory enzyme in glycolysis, has homologous N- and C-terminal domains thought to result from duplication, fusion, and divergence of an ancestral prokaryotic gene. It has been suggested that both the active site and the fructose 2,6-P<sub>2</sub> allosteric site are formed by opposing N- and C-termini of subunits oriented antiparallel in a dimer. On the contrary, we show here that in fact the N-terminal halves form the active site, since expression of the N-terminal half of the enzymes from <i>Dictyostelium discoideum</i> and human muscle in phosphofructokinase-deficient yeast restored growth on glucose. However, the N-terminus alone was not stable <i>in vitro</i>. The C-terminus is not catalytic but is needed for stability of the enzyme, as is the connecting peptide that normally joins the two domains (here included in the N-terminus). Co-expression of homologous, but not heterologous, N- and C-termini yielded stable, fully active enzymes <i>in vitro</i> with sizes and kinetic properties similar to those of the wild type tetrameric enzymes. This indicates that the separately translated domains can fold sufficiently well to bind to each other, that such binding of complementary domains is stable and that the alignment is sufficiently accurate and tight as to preserve metabolite binding sites and allosteric interactions.]]></description>
	<dc:creator>O H. Mart&#x00ED;nez-Costa, V S&#x00E1;nchez, A L&#x00E1;zaro, E D. Hern&#x00E1;ndez, K Tornheim, J J. Arag&#x00F3;n</dc:creator>
	<dc:date>2012-04-25T09:49:43Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20120173</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-04-25</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112142">
	<title><![CDATA[Mitochondrial Stress causes Increased Succination of Proteins in Adipocytes in Response to Glucotoxicity]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112142</link>
	<description><![CDATA[S-(2-succino)-cysteine (2SC) is a chemical modification formed by a Michael addition reaction of fumarate with cysteine residues in proteins. Formation of 2SC, termed <i>succination </i>of proteins, increases in adipocytes grown in high glucose medium and in adipose tissues of type 2 diabetic mice. However, the metabolic mechanisms leading to increased fumarate and succination of protein in the adipocyte are unknown. Treatment of 3T3 cells with high glucose (30 mM vs. 5 mM) caused a significant increase in cellular ATP/ADP, NADH/NAD<sup>&#x002B;</sup>, and the mitochondrial membrane potential. There was also a significant increase in cellular fumarate concentration and succination of proteins, which may be attributed to the increase in NADH/NAD<sup>&#x002B;</sup> and subsequent inhibition of Krebs cycle NAD<sup>&#x002B;</sup>-dependent dehydrogenases. Chemical uncouplers, which dissipated the mitochondrial membrane potential and reduced the NADH/NAD&#x00AD;<sup>&#x002B; </sup>ratio, also decreased fumarate concentration and protein succination. High glucose plus metformin, an inhibitor of Complex I in the electron transport chain, caused an increase in fumarate and succination of protein. Thus, excess fuel supply (glucotoxicity) appears to create a pseudohypoxic environment (high NADH/NAD<sup>&#x002B;</sup> without hypoxia), which drives the increase in succination of protein. We propose that increased succination of proteins is an early marker of glucotoxicity and mitochondrial stress in adipose tissue in diabetes.]]></description>
	<dc:creator>N Frizzell, S A Thomas, J A Carson, J W Baynes</dc:creator>
	<dc:date>2012-04-24T10:00:12Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112142</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-04-24</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112225">
	<title><![CDATA[Characterization of pyrimidine nucleoside phosphorylase of Mycoplasma hyorhinis: implications for the clinical efficacy of nucleoside analogues]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112225</link>
	<description><![CDATA[We demonstrate that the cytostatic and antiviral activity of pyrimidine nucleoside analogues is markedly decreased by a <i>Mycoplasma</i> <i>hyorhinis </i>infection and show that the phosphorolytic activity of the mycoplasmas is responsible for this. Since mycoplasmas are (i) an important cause of secondary infections in immunocompromised (e.g. HIV-infected) patients, and (ii) known to preferentially colonize tumor tissue in cancer patients, catabolic mycoplasma enzymes may compromise efficient chemotherapy of virus infections and cancer. In the genome of <i>M. hyorhinis</i>, a <i>thymidine phosphorylase (TP)</i> gene has been annotated. This gene was cloned, expressed in <i>Escherichia coli</i> and kinetically characterized. Whereas the mycoplasma TP efficiently catalyzes the phosphorolysis of thymidine (<i>K</i><sub>m</sub> = 473 &#x00B5;M) and deoxyuridine (<i>K</i><sub>m</sub> = 578 &#x00B5;M), it prefers uridine (<i>K</i><sub>m</sub> = 92 &#x00B5;M) as a substrate. Our kinetic data and sequence analysis revealed that the annotated <i>M. hyorhinis </i>TP belongs to the nucleoside phosphorylase (NP)-II class pyrimidine nucleoside phosphorylases (PyNP), and is distinct from the NP-II class TP and NP-I class uridine phosphorylases (UP)<i>.</i> <i>M. hyorhinis</i> PyNP also markedly differs from TP and UP in its substrate specificity towards therapeutic nucleoside analogues and susceptibility to clinically relevant drugs. Several kinetic properties of mycoplasma PyNP were explained by <i>in silico</i> analyses.]]></description>
	<dc:creator>J Vande Voorde, F Gago, K Vrancken, S Liekens, J Balzarini</dc:creator>
	<dc:date>2012-04-04T14:17:03Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112225</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-04-04</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112200">
	<title><![CDATA[Fe-heme bound to Escherichia coli bacterioferritin accelerates iron core formation by an electron transfer mechanism]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112200</link>
	<description><![CDATA[Bacterioferritin (BFR) is an iron storage and detoxification protein that differs from other ferritins by its ability to bind heme cofactors. Heme bound to BFR is believed to be involved in iron release, and was previously thought not to play a role in iron core formation. Investigation of the effect of bound heme on formation of the iron core has been enabled in the present work by development of a method for reconstitution of BFR from <i>Escherichia coli</i> with exogenously added heme at elevated temperature in the presence of a relatively high concentration of sodium chloride. Kinetic analysis of iron oxidation by <i>E. coli</i> BFR preparations containing varying amounts of heme revealed that heme bound to BFR decreases the rate of iron oxidation at the dinuclear iron ferroxidase sites but increases the rate of iron core formation. Similar kinetic analysis of BFR reconstituted with cobalt-heme revealed that this heme derivative has no influence on the rate of iron core formation. These observations argue that heme bound to <i>E. coli</i> BFR accelerates iron core formation by an electron transfer-based mechanism.]]></description>
	<dc:creator>S G. Wong, R Abdulqadir, N E Le Brun, G R Moore, A Grant Mauk</dc:creator>
	<dc:date>2012-03-30T10:09:09Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112200</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-03-30</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120294">
	<title><![CDATA[Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120294</link>
	<description><![CDATA[Recent studies have highlighted the fact that cancer cells have an altered metabolic phenotype, and this metabolic reprogramming is required to drive biosynthesis pathways necessary for rapid replication and proliferation. Specifically, the importance of citric acid cycle-generated intermediates in the regulation of cancer cells proliferation has been recently appreciated. One function of monocarboxylate transporters (MCTs) is to transport the citric acid cycle substrate pyruvate across the plasma membrane and into mitochondria, and inhibition of MCTs has been proposed as a therapeutic strategy to target metabolic pathways in cancer. Here, we examined the effect of different metabolic substrates (glucose and pyruvate) on mitochondrial function and proliferation in breast cancer cells. We demonstrated that cancer cells proliferate more rapidly in the presence of exogenous pyruvate when compared to lactate. Pyruvate supplementation fueled mitochondrial oxygen consumption and the reserve respiratory capacity, and this increase in mitochondrial function correlated with proliferative potential. In addition, inhibition of cellular pyruvate uptake using the MCT inhibitor &#x03B1;-cyano-4-hydroxycinnamic acid impaired mitochondrial respiration and decreased cell growth. These data demonstrate the importance of mitochondrial metabolism in proliferative responses and highlight a novel mechanism of action for MCT inhibitors through suppression of pyruvate-fueled mitochondrial respiration.]]></description>
	<dc:creator>A R Diers, K A Broniowska, C Chang, N Hogg</dc:creator>
	<dc:date>2012-03-30T09:49:50Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20120294</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-03-30</prism:publicationDate>
	<prism:section>BJ Energy</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120197">
	<title><![CDATA[A Functional Description of CymA, an Electron Transfer Hub Supporting Anaerobic Respiratory Flexibility in Shewanellae.]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120197</link>
	<description><![CDATA[CymA is a member of the NapC/NirT-family of quinol dehydrogenases. Essential for the anaerobic respiratory flexibility of shewanellae, CymA transfers electrons from menaquinol to various dedicated systems for the reduction of terminal electron acceptors including fumarate and insoluble minerals of Fe(III). Spectroscopic characterisation of CymA from <i>Shewanella oneidensis</i> MR-1 identifies three low-spin His/His coordinated <i>c</i>-hemes and a single high-spin <i>c</i>-heme with His/H<sub>2</sub>O coordination lying adjacent to the quinol binding site. At pH 7, binding of the menaquinol analogue, 2-heptyl-4-hydroxyquinoline-N-oxide, does not alter the mid-point potentials of the high-spin (ca. -240 mV) and low-spin (ca. -110, -190 and -265 mV) hemes that appear biased to transfer electrons from the high- to low-spin centres following quinol oxidation. CymA is reduced with menadiol (<i>E</i><sub>m</sub> -80 mV) in the presence of NADH (<i>E</i><sub>m</sub> -320 mV) and an NADH:menadione oxidoreductase, but not by menadiol alone. In cytoplasmic membranes reduction of CymA may then require the thermodynamic driving force from NADH, formate or H<sub>2 </sub>oxidation as the redox poise of the menaquinol pool in isolation is insufficient. Spectroscopic studies suggest that CymA requires a non-heme cofactor for quinol oxidation and that the reduced enzyme forms a 1:1 complex with its redox partner Fcc<sub>3</sub>. The implications for CymA supporting the respiratory flexibility of shewanellae are discussed.]]></description>
	<dc:creator>S J Marritt, T G Lowe, J Bye, D G G McMillan, L Shi, J Fredrickson, J Zachara, D J Richardson, M R Cheesman, L J C Jeuken, J N Butt</dc:creator>
	<dc:date>2012-03-29T14:13:17Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20120197</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-03-29</prism:publicationDate>
	<prism:section>BJ Energy</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111890">
	<title><![CDATA[Estrogen causes ATBF1 protein degradation through the estrogen-responsive E3 ubiquitin ligase EFP]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111890</link>
	<description><![CDATA[We previously revealed that tumor suppressor ATBF1 formed an autoregulatory feedback loop with estrogen-ER&#x03B1; signaling to regulate estrogen-dependent cell proliferation in breast cancer cells. In this loop, ATBF1 inhibits the function of estrogen-ER&#x03B1; signaling while ATBF1 protein levels are fine-tuned by estrogen-induced transcriptional upregulation as well as ubiquitin proteasome pathway (UPP)-mediated protein degradation. Here we show that the estrogen-responsive finger protein (EFP) is an E3 ubiquitin ligase mediating estrogen-induced ATBF1 protein degradation. Knockdown increases but overexpression of EFP decreases ATBF1 protein levels. EFP interacts with and ubiquitinates ATBF1 protein. Furthermore, we show that EFP is an important factor in estrogen-induced ATBF1 protein degradation in which some other factors are also involved. In human primary breast tumors, due to both as directly-upregulated ER&#x03B1; target gene products, the levels of ATBF1 protein are positively correlated with the levels of EFP protein. However, the ratio of ATBF1 protein to EFP protein is negatively correlated with EFP protein levels. Functionally, ATBF1 antagonizes EFP-mediated cell proliferation. These findings not only establish EFP as the E3 ubiquitin ligase for estrogen-induced ATBF1 protein degradation, but further support the autoregulatory feedback loop between ATBF1 and estrogen-ER&#x03B1; signaling and thus implicate ATBF1 in estrogen-dependent breast development and carcinogenesis.]]></description>
	<dc:creator>X Dong, X Fu, S Fan, P Guo, D Su, J Dong</dc:creator>
	<dc:date>2012-03-28T10:46:12Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111890</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-03-28</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120163">
	<title><![CDATA[Effects of a Glucokinase Activator on Hepatic Intermediary Metabolism: Study With 13C Isotopomer-Based Metabolomics]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20120163</link>
	<description><![CDATA[Glucokinase activators (GKAs) are promising agents for the therapy of Type-2 diabetes, but little is known about their effects on hepatic intermediary metabolism. We monitored the fate of 13C-labeled glucose in both liver perfusion system and isolated hepatocytes. Mass spectrometry and nuclear magnetic resonance spectroscopy were deployed to measure isotopic enrichment. The results demonstrate that the stimulation of glycolysis by GKA led to numerous changes in hepatic metabolism: <b>(i)</b> Augmented flux through the TCA cycle, as evidenced by larger incorporation of <sup>13</sup>C into the cycle (anaplerosis) and increased generation of <sup>13</sup>C isotopomers of citrate, glutamate and aspartate (cataplerosis); <b>(ii)</b> Lowering of hepatic [Pi] and elevated [ATP], denoting greater phosphorylation potential and energy state; <b>(iii) </b>Stimulation of glycogen synthesis from glucose but inhibition of glycogen synthesis from 3-carbon precursors; <b>(iv)</b> Increased synthesis of N-acetlylglutamate and consequently augmented ureagenesis; <b>(v)</b> Increased synthesis of glutamine, alanine, serine and glycine; and <b>(vi) </b>Increased production and outflow of lactate. The current study provides a deeper insight into the hepatic actions of GKAs and uncovers the potential benefits and risks of GKA for treatment of diabetes. GKA improved hepatic bioenergetics, ureagenesis and glycogenesis but decreased gluconeogenesis with a potential risk of lactic acidosis and fatty liver.]]></description>
	<dc:creator>I Nissim, O Horyn, I Nissim, Y Daikhin, S L. Wehrli, M Yudkoff, F M. Matschinsky</dc:creator>
	<dc:date>2012-03-26T13:56:40Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20120163</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-03-26</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112079">
	<title><![CDATA[Structure-based analysis of VDAC1: N-terminus location, translocation, channel gating and association with anti-apoptotic proteins]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112079</link>
	<description><![CDATA[Structural studies place the VDAC N-terminal region within the channel pore. Biochemical and functional studies, however, reveal that the N-terminal domain is cytoplasmically exposed. Here, the location and translocation of the VDAC1 N-terminal domain, and its role in voltage-gating and as a target for anti-apoptotic proteins, were addressed. Site-directed mutagenesis and cysteine substitution, together with a thiol-specific cross-linker, served to show that the VDAC1 N-terminal region exists in a dynamic equilibrium, located within the pore or exposed outside the &#x03B2;-barrel. Using single cysteine-bearing VDAC1, we demonstrate that the N-terminal region lies inside the pore. However, the same region can be exposed outside the pore, where it dimerizes with the N-terminal domain of a second VDAC molecule. When the N-terminal region a-helix structure was perturbed, intra-molecular cross-linking was abolished and dimerization was enhanced. This mutant also displays reduced voltage-gating and less binding of hexokinase but not of the anti-apoptotic proteins, Bcl2 and Bcl-xL. Replacing glycines in the N-terminal domain glycine-rich sequence (GRS) yielded less intra-molecular cross-linked product but more dimerization, suggesting that GRS provides the flexibility needed for N-terminal translocation from the internal pore to the channel face. N-terminal mobility may thus contribute to channel gating and interaction with anti-apoptotic proteins.]]></description>
	<dc:creator>S Geula, D Ben-Hail, V Shoshan-Barmatz</dc:creator>
	<dc:date>2012-03-08T12:29:12Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112079</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-03-08</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

</rdf:RDF>

